Kornimate/medical-research-clean huggingface dataset:
the influence of intensive education and coaching on compliance for oral ganciclovir in the prophylaxis of cmv: an open randomised trial

Conditions: Cytomegalovirus Infections

Summary: 21 patients were randomised to receive instructions and coaching or no intervention on the use and intake of ganciclovir. intake of medication was measured by an electronic pill box. the duration of the study was 100 days.


Eligibility criteria:
inclusion criteria: * men and women between 18 and 65 years old * de novo kidney transplant patients * patients who need cmv prophylaxis with ganciclovir during 3 months * patients who gave informed consent after an oral explanation of the study exclusion criteria: * patients who are seronegative for cmv virus and who received a kidney from a cmv negative donor * patients with a creatinin clearance of less than 10 ml/min

Keywords: the effect of information on compliance of medication
patient-ventilator dyssynchrony: how is the effect of management?

Conditions: Respiratory Failure

Summary: although patient-ventilator asynchrony is a frequent phenomenon, its course following management is unknown. as the aid of a data recording system, we try to observe the consequence of patient-ventilator asynchrony following management. our target is aimed at the patients with high asynchronization index ( \> 10%) as this group of patients have been shown to have prolonged course in intensive care unit and are also prone to be tracheostomized


Eligibility criteria:
inclusion criteria: * patients admitted to respiratory intensive care unit with acute respiratory failure and presence of patient-ventilator asynchrony(ai of more than 10%) * patient can trigger the ventilator exclusion criteria: * high oxygen fraction: \> 60%. * high peep need: \> 12cmh2o. * hemodynamic unstable: shock * central nervous system problem. * hyperacitve delirium * without informed consent

Keywords: ventilator patient-ventilator asynchrony
a single group study to evaluate the effects of a topical product on cramps associated with the menstrual cycle

Conditions: Dysmenorrhea; Menstrual Cramps

Summary: this study evaluates the effectiveness of a topical product in reducing discomfort associated with menstrual cramps and back pain. participants will apply the product during two menstrual cycles and complete study-specific questionnaires to assess the impact on symptoms and user perceptions.


Eligibility criteria:
inclusion criteria: * female, aged 18-35. * has had a regular menstrual cycle for the past six months and is to predict their menstrual cycle and the timing of their menstruation. * mild to moderate self-reported discomfort during menstruation related to pelvic cramps and back pain. * generally healthy and not living with any uncontrolled chronic disease. * has a menstrual cycle between 21 and 35 days in length. * willing to maintain current diet, sleep, and activity level for the duration of the study. * resides in the united states. exclusion criteria: * any pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders. * current use of any blood thinning medication. * anyone with known severe allergic reactions. * anyone with any allergies requiring the use of an epi-pen. * anyone with any allergies or sensitivities to any of the study product ingredients. * anyone who is pregnant, breastfeeding, or trying to conceive currently or at any point until the end of the study period. * anyone unwilling to follow the study protocol. * anyone taking prescription medications for acute or chronic pain. * anyone with a diagnosis of a condition relating to the menstrual cycle or reproductive system-e.g., polycystic ovary syndrome (pcos), premenstrual dysphoric disorder (pmdd), endometriosis, etc. * anyone diagnosed with other conditions that may cause lower back, abdominal, or pelvic discomfort- e.g., fibromyalgia, crohn's, ibs, uc, chronic constipation, frequent utis, bacterial vaginosis (bv), or history or kidney stones. * anyone who has changed their birth control in the past three months. * anyone who has had any surgeries or invasive treatments in the past six months or has any planned up until the end of the study period. * anyone with any major illness in the past three months. * anyone currently experiencing symptoms associated with perimenopause. * anyone taking part in any other clinical trials or studies during this study's duration. * anyone with a history of substance abuse. * anyone who is currently a smoker or has been in the past three months.

Keywords: headaches mood changes fatigue
atc vs psv for ventilatory weaning of pediatrics postcardiac surgery

Conditions: Congenital Heart Disease

Summary: the ventilator modality of automatic tube compensation (atc) can provide variable pressure supports during the weaning process to overcome any change in the resistance of the breathing circuit, endotracheal tube, and airways. the aim of the study is to evaluate the automatic tube compensation (atc) as a tool for ventilatory weaning in pediatrics after surgeries for congenital cardiac anomalies.

the ventilator modality of automatic tube compensation (atc) can provide variable pressure supports during the weaning process to overcome any change in the resistance of the breathing circuit, endotracheal tube, and airways. atc is effective in overcoming the work of breathing caused by airway resistance to allow successful weaning process and extubation. pressure support ventilation (psv) has been widely used in the performance of a spontaneous breathing trial because it can compensate to some extent for the additional work of breathing imposed by the endotracheal tube and the breathing circuit. however, it is difficult to recognise the exact pressure support to overcome the tubing resistance during the weaning process till extubation. the aim of the study is to evaluate the automatic tube compensation (atc) as a tool for ventilatory weaning in pediatrics after surgeries for congenital cardiac anomalies. the primary objective of our study is to compare the efficacy of atc versus ps as a modality for ventilatory weaning of pediatric postcardiac surgery as regards effects on work of breathing, lung compliance, and alveolar recruitment. the secondary objective is to determine perioperative predictors of extubation failure (requirement for reintubation and mechanical ventilation after prior successful weaning from ventilation, within 48 hours after extubation) after cardiac surgery. patients will be included after fulfilling weaning criteria and being pain free. a weaning trial for 30 minutes will be commenced according to the following and assessed by the attending physician:- group a: weaning trial will be done for 17 patients using psv 0 cmh2o with 100% automatic tube compensation (atc). group p: weaning trial will be done for 17 patients using psv 8 cmh2o without atc.

Eligibility criteria:
inclusion criteria: * pediatric patients (age 8 months to 12 years) who will undergo congenital cardiac surgeries with the same general anesthetic technique and pecto-intercostal fascial plane block (pifb) as regional analgesia for pain management. exclusion criteria: * (1) duration of mechanical ventilation is more than 48 hours; (2) patients on high inotropic support (unstable hemodynamics); (3) patients with disturbed conscious level; (4) patients with palliative cardiac shunting procedures (e.g., bt shunt, glenn shunt).
effects of gabaa receptor modulation by ap-325 on insulin secretion in patients with type 2 diabetes

Conditions: Type2 Diabetes

Summary: the aim of this single-center, prospective, randomized, double-blind, placebo-controlled, 2-arm parallel-group interventional study is to investigate the effect of 4-week treatment with ap-325 on c-peptide release as measure of insulin secretion compared to placebo in type 2 diabetes (t2d) patients.


Eligibility criteria:
inclusion criteria: * diagnosis of t2d * age between 25 and 75 years * hba1c ≥6.5 and ≤9.5 % * bmi ≤ 45 kg/m2 * treatment-naive or stable antihyperglycemic therapy with metformin, α-glucosidase-inhibitor and/or sglt2 inhibitor * ability to give consent exclusion criteria: * acute infections (hscrp \> 5mg/dl, body temperature \>37.5°c) * insulin therapy or treatment with sulfonylureas, glinides, glp-1 receptor agonists, thiazolidinediones; current treatment with dpp-4 inhibitors or during the 4 weeks prior to baseline examination * uncontrolled hyperglycemia, e.g. fasting blood glucose \>240 mg/dl * heart rate \ 100 beats per minute; systolic blood pressure \ 160 mmhg; diastolic blood pressure \ 100 mmhg; uncontrolled hypertension * creatinine clearance \<60 ml/min (egfr by mdrd formula) * severe chronic illnesses, such as congestive heart failure (nyha iii/iv), liver insufficiency (child-pugh class b/c), history of acute coronary syndrome, stroke * anemia (hb \<12 g/l for men, hb \<11 g/l for women) * participation in another intervention study within 2 months before the examination * hypersensitivity against ap-325, placebo or other ingredients of imp * immunocompromising diseases * immunomodulatory drugs (e.g. oral cortisone preparations, biologicals) * thyroid diseases with an unstable metabolic state (change in l-thyroxine dose within the past 6 weeks, tsh and ft4 outside the normal range) * planned pregnancy, pregnant or lactating women, positive pregnancy test, and woman of childbearing potential not using two adequate methods of contraception, including a barrier method and a highly efficacious non-barrier method * past (≤ 5 years) or current history of psychiatric disorders, including psychiatric depression * hiv, hepatitis b or c disease * previous / current alcohol and / or drug abuse * malignant cancer * bia and mr-incompatible metal or magnetic implants, devices or objects inside of or on the body, claustrophobia * treatment with the following drug groups or agents: anticoagulant drugs (exception: acetylsalicylic acid 100 mg/day), dihydropyridines (e.g. nifedipine, amlodipine), azilsartan, losartan and irbesartan, celecoxib; if applicable, other drugs that are predominantly metabolized by cyp2c9 * inhibitors or inducers of cyp2c9, cyp3a4, such as amiodarone, verapamil, rifampicin * poor cyp2c9 metabolizer

Keywords: type 2 diabetes diabetes mellitus gabaa receptor β-cell function glycemic control
interest of the manual exploration as a supplement to the coelioscopy in the evaluation of the resectability of peritoneal carcinosis

Conditions: Ovarian Cancer With Peritoneal Carcinosis

Summary: this is a multicenter prospective diagnostic study.


Eligibility criteria:
inclusion criteria: * over 18 years of age patient * woman presenting a peritoneal carcinosis presumed ovarian origin * coelioscopy (1st intent or recurrence) planned or performed in the last 4 weeks for laparotomy. the peritoneal cancer index of sugarbaker must be available. * who 0 - 2 * membership in a social security system * patient having given her written consent exclusion criteria: * male * contraindication in the coelioscopy * any associated medical or psychological condition which could compromise the capacity of the patient to participate in the study * patient deprived of freedom, under guardianship or guardianship

Keywords: ovarian cancer peritoneal carcinosis manual exploration surgery gelport
early weaning from incubator to crib

Conditions: Hypothermia, Newborn; Body Temperature Changes; Newborn Thermal Injury

Summary: the purpose of this study is to determine the safety and feasibility of weaning from the incubator at a lower post-natal weight at 1600 grams. our hypothesis is that early weaning from the incubator to a crib/bassinet is safe and may result in a decrease in length of hospital stay while maintaining appropriate growth velocity. specific outcomes the investigators will evaluate are the length of hospital stay and growth velocity at early weaning.


Eligibility criteria:
inclusion criteria: * infants with a birth weight \<1600 gm exclusion criteria: * infants who have bradycardia (hr\<80 bpm) that require stimulation for resolution. * infants who require phototherapy. * infants who require respiratory support \>2 liter per minute flow by nasal cannula, oxygen need can vary between 21-100%. * infants with major congenital anomalies
efficacy and safety study of concurrent chemoradiation therapy to treat locally advanced cervical cancer

Conditions: Cervical Cancer

Summary: concurrent chemoradiation therapy with weekly cisplatin is the current standard treatment for patients with locally advanced cervical cancer. however, weekly cisplatin is related to renal toxicity and not convenient regimen. recently, carboplatin has proved to be a good radiosensitizer and less renal toxicity. weekly carboplatin is more convenient regimen for both patients and physicians. weekly carboplatin may have similar efficacy with weekly cisplatin and may have more favorable toxicity profile. therefore, the investigators aimed to evaluate the efficacy and safety of concurrent chemoradiation with weekly carboplatin in patients with locally advanced cervical cancer.


Eligibility criteria:
inclusion criteria: * previously untreated, histologically confirmed cervical cancer * one of following histologic types squamous carcinoma, adenocarcinoma, adenosquamous carcinoma * age: 20-75 years * gog performance status: 0-2 * adequate organ function bone marrow: wbc ≥ 3,000/mm3, anc ≥ 1,500/mm3, platelet ≥ 100x103/mm3, hb ≥ 10.0 g/dl kidney: creatinine \< 1.25 × unl, liver : ast, alt \< 3 × unl, t- bilirubin \< 1.5 mg/ mm3 * contraception during study treatment * informed consent exclusion criteria: * previous chemotherapy or pelvic radiation therapy * hormone therapy within 4 weeks * concomitant malignancy within 5 years except cured basal cell carcinoma of skin * uncontrolled medical disease * pregnant or lactating woman * etc.
3h of pne on bdnf and pain levels

Conditions: Chronic Pain; Musculoskeletal Pain

Summary: the promotion of neuroplasticity in conjunction with strategies for restructuring maladaptive cognitions that largely cause the activation of neural networks that contribute to the perpetuation of pain is therefore a fundamental neurophysiological principle for establishing a neurophysiological basis for pain. perpetuation of pain, is therefore a fundamental neurophysiological principle for establishing physiotherapy therapeutic to establish therapeutic strategies from physiotherapy that contribute to improve the quality of life of patients with chronic pain. based on the theory that neurotrophic factors such as bdnf play a fundamental role in the initiation and or maintenance of hyperexcitability of central neurons in pain, we consider that the levels of this neurotrophic factor, such as bdnf, may have an important role in the perpetuation of pain. that the levels of this neurotrophic factor may be modified by the application of a therapeutic education protocol, favoring therapeutic education protocol, favoring a reduction in pain intensity.


Eligibility criteria:
inclusion criteria: * males and females aged 18 to 65 years with musculoskeletal pain for a minimum of 3 months * patients recruited by information pamphlets from the university clinic of the rey juan carlos university, and cseu la salle * ability to perform all the clinical tests and to understand the study process, as well as to obtain informed consent. exclusion criteria: -systemic, neurological, oncological or inflammatory diseases; psychiatric pathologies, pregnancy, type ii diabetes.

Keywords: bdnf pain neuroscience education
utility of single-dose oral antibiotic prophylaxis in prevention of surgical site infection in dermatologic surgery

Conditions: Surgical Site Infection

Summary: the purpose of the study is to assess the effectiveness of a single dose of preoperative antibiotic in reducing surgical site infections in certain dermatological procedures. patients will undergo surgical excision or mohs surgery as is clinically indicated and part of usual care. the study will be a double blinded, placebo-controlled clinical trial. patients meeting inclusion criteria will be assigned to one of three participant categories: 1) patients undergoing repair with skin flap or graft on the nose, 2) patients undergoing repair with skin graft, flap, or wedge resection on the ear, or 3) patients undergoing mohs surgery with closure or partial closure or surgical excision on the lower extremity below the knee. within each category, participants will be randomized into one of two groups: group one will receive a preoperative placebo pill and group two will receive preoperative antibiotic prophylaxis (either a single dose of cephalexin 2g po or single dose of clindamycin hydrochloride 600 mg po if allergy to penicillin or cephalosporin). patients will followed for 30 days +/- 7 after surgery to evaluate for any surgical site infection.


Eligibility criteria:
inclusion criteria: * 18 years of age or older * presenting to carilion clinic dermatology and mohs surgery in roanoke, va at riverside 1 * suspected to undergo a single-staged repair including a skin flap or graft on the nose * or suspected to undergo single-staged repair including a skin graft or flap or wedge resection 1 on the ear * or undergoing mohs with closure or partial closure or surgical excision on the lower extremity below the knee exclusion criteria: * patients with intellectual or mental impairment affecting ability to give informed consent * use of any antibiotic (other than intervention) within 48 hours of the surgery suspected infection at time of surgery * inability to take cephalexin or clindamycin hydrochloride due to allergy or intolerance current inflammatory skin disease affecting the surgical site * patients undergoing concurrent surgery to oral or nasal mucosa * patients who have had a recent prosthetic joint surgery within two years and have been told they require antibiotic prophylaxis. * patients who are currently pregnant, concerned they could be pregnant, actively trying to conceive, or missed last menstrual period that is not explainable by a birth control method.
evaluation of the effect of drug-related problems in pulmonary embolism

Conditions: Pulmonary Thromboembolisms

Summary: pulmonary embolism (pe) presents notable risks of morbidity and mortality, underscoring the need for customized anticoagulant treatment. there is a scarcity of research examining drug-related issues (drps) in pe. this research endeavor seeks to assess how addressing drps affects the clinical outcomes of pe patients receiving outpatient care, offering valuable insights to bolster patient safety measures. this study will conduct a randomized controlled trial on pe patients in istanbul, turkey, from january 15, 2022, to january 15, 2023. the intervention group (ig) will receive clinical pharmacist (cp) recommendations for drps, while the control group (cg) will undergo observation only. evaluations will occur at 90- and 180-days post-discharge, focusing on drps, cp interventions, and patient outcomes. data will be systematically recorded and analyzed, adhering to ethical standards and employing the pcne v9.1 classification system.

pulmonary embolism (pe) involves the blockage of the pulmonary artery or one of its branches by materials like thrombus from elsewhere in the body. this condition is linked to increased mortality and morbidity rates, and if left untreated, it can result in recurring episodes. additionally, using anticoagulant therapy poses a significant risk of severe bleeding. recent guidelines recommend customizing the duration of pe treatment based on the type of underlying risk factor, distinguishing between transient and persistent factors. prolonged treatment without a persistent risk factor may heighten the risk of bleeding. hence, selecting appropriate treatment options tailored to individual patient needs is crucial. the main goal of our study is to evaluate how managing drug-related problems (drps) in pulmonary embolism (pe) outpatients influences their clinical outcomes. this research aims to provide valuable insights into the effectiveness of interventions targeting drps within the framework of pe management .

Eligibility criteria:
inclusion criteria: 1. a confirmed diagnosis of pulmonary embolism (icd-10 code: i26.0) 2. patients visited the chest diseases outpatient clinic for post-discharge follow-up 3. being 18 years or older. 4. patients who could be evaluated by the clinical pharmacist for at least 24 hours within the intervention group. exclusion criteria: 1. being under 18 years old. 2. lost follow up in 90th day after pulmonary embolism.

Keywords: pulmonary embolism bleeding clinical pharmacist drug-related problems anticoagulation
ammonia metabolism assessed by ammonia infusion

Conditions: Ammonia; Metabolic Disorder; Liver Failure, Chronic

Summary: the present study will develop a method to assess ammonia metabolism by ammonia infusion and investigate ammonia production and clearance in healthy individuals and in patients with liver cirrhosis.


Eligibility criteria:
inclusion criteria - healthy controls: * alcohol \< 40g/day * bmi \< 30 * diseased or medicated inclusion criteria - patients with cirrhosis: * child-pugh a or b cirrhosis * bmi \< 30 exclusion criteria: * child-pugh score c * kidney failure (egfr \< 60 ml/min/1.73m2) * overt hepatic encephalopathy or more than one previous 1 episode of overt hepatic encephalopathy * acute bacterial infection * cancer * diabetes * ammonia-targeted treatment of hepatic encephalopathy other than lactulose (including rifaximin and branched-chain amino acids)
pins stimulator system for deep brain stimulation of the nucleus accumbens to treat severe opioid addiction

Conditions: Opioid Addiction

Summary: the purpose of this study is to verify efficacy and safety of a bilateral deep brain stimulation (dbs) of the nucleus accumbens (nac) as a treatment option for severe opioid addiction.


Eligibility criteria:
inclusion criteria: 1. age \> 18 years old. 2. in accordance with the diagnostic standards of dsm-iv \& icd-10 for addicted and dsm-iv for abstinence. 3. qualitative urine detection for opioids showing positive result. 4. cleared for 8 to 36 hours after their last drug taking. 5. fully understood and signed on informed consent. exclusion criteria: 1. person with consciousness disorder on opioid abstinence, seriously aggressive, heavily dehydrated and intending to commit suicide. 2. patients with serious liver and kidney dysfunction, pulmonary decompensation, or complicated with serious damage in other systems. 3. patients with serious infectious disease. 4. patients with history of serious neurological or psychiatrical diseases. 5. person with history of hiv infection or serious malnutrition. 6. dependent upon and addicted to multiple drugs. 7. attended some other drug trials within one month.